Skip to main content
Erschienen in:

07.01.2022 | Original Article

Relation Between Posterior Canal Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency

verfasst von: Kanika Sharma, Tarun Ojha, Rajendra Dabaria, Biban Chhabra, Bhargavi Bhaskar Trivedi, Monika Bansal

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 3/2022

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to establish a relationship between vitamin D levels and benign paroxysmal positional vertigo (BPPV) and its recurrence; and to evaluate the remedial effect of vitamin D on BPPV. In a pilot study, 40 patients with clinically diagnosed posterior canal BPPV were evaluated, treated and were followed up for a period of 6 months at ENT Department of Mahatma Gandhi Medical College, Jaipur. All the patients with clinical diagnosis of posterior canal BPPV were tested for 25(OH)D levels at their 1st visit. Patients were divided in two groups after appropriate matching. Group A was given vitamin D supplementation along with canal repositioning manoeuvre (CRM) and group B were only treated by canal repositioning manoeuvre. Patients underwent neuro-otological assessment during follow up visits and recurrent attacks were recorded. This study was conducted on 40 patients with BPPV (26 females and 14 males). The average age was 50 years. Average serum of 25(OH)D at the first visit was (12.2 ng/ml) for group A, and (12.4 ng/ml) for group B, all patients had low serum level of 25(OH)D (below 20 ng/ml). Recurrent BPPV episodes, were significantly lower in group A than that of group B. We second the hypothesis that the patients with BPPV who have insufficient levels of Vitamin D may benefit from vitamin D supplementation and we suggest further epidemiological and pharmacological studies to detect the effect of vitamin D deficiency on development and recurrence of vertigo.
Literatur
2.
Zurück zum Zitat Gu X (2018) Analysis of effect of 1α-hydroxyvitamin D3 on benign paroxysmal positional vertigo and risk factors. Published online 2018 Jan Gu X (2018) Analysis of effect of 1α-hydroxyvitamin D3 on benign paroxysmal positional vertigo and risk factors. Published online 2018 Jan
3.
Zurück zum Zitat Sturges M, Canell J (2015) Treating vitamin D deficiency may help reduce the recurrence rate of vertigo, according to study Sturges M, Canell J (2015) Treating vitamin D deficiency may help reduce the recurrence rate of vertigo, according to study
4.
Zurück zum Zitat Talaat HS, Abuhadied G, Talaat AS et al (2015) Low bone mineral density and vitamin D deficiency in patients with benign positional paroxysmal vertigo. Eur Arch Otorhinolaryngol 272(9):2249–2253CrossRef Talaat HS, Abuhadied G, Talaat AS et al (2015) Low bone mineral density and vitamin D deficiency in patients with benign positional paroxysmal vertigo. Eur Arch Otorhinolaryngol 272(9):2249–2253CrossRef
5.
Zurück zum Zitat Eur Arch Otorinolaryngology. Low bone mineral desity and vit D deficiency in patients with BPPV, 2015 Eur Arch Otorinolaryngology. Low bone mineral desity and vit D deficiency in patients with BPPV, 2015
6.
Zurück zum Zitat Yamauchi D, Raveendran NN, Pondugula SR et al (2005) Vitamin D upregulates expression of ECaC1 mRNA in semicircular canal. Biochem Biophys Res Commun 331(4):1353–1357CrossRef Yamauchi D, Raveendran NN, Pondugula SR et al (2005) Vitamin D upregulates expression of ECaC1 mRNA in semicircular canal. Biochem Biophys Res Commun 331(4):1353–1357CrossRef
7.
Zurück zum Zitat Yang CJ, Kim Y, Lee HS et al (2017) Bone mineral density and serum 25-hydroxyvitamin D in patients with idiopathic benign paroxysmal positional vertigo. J Vestib Res 27(5–6):287–294 Yang CJ, Kim Y, Lee HS et al (2017) Bone mineral density and serum 25-hydroxyvitamin D in patients with idiopathic benign paroxysmal positional vertigo. J Vestib Res 27(5–6):287–294
8.
Zurück zum Zitat Minasyan A, Keisala T, Zou J, Zhang Y, Toppila E, Syvälä H, Lou YR, Kalueff AV, Pyykkö I, Tuohimaa P, (2009) Vestibular dysfunction in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 114:161–166CrossRef Minasyan A, Keisala T, Zou J, Zhang Y, Toppila E, Syvälä H, Lou YR, Kalueff AV, Pyykkö I, Tuohimaa P, (2009) Vestibular dysfunction in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 114:161–166CrossRef
9.
Zurück zum Zitat Gu X, Dong F, Gu J (2018) Analysis of effect of 1α-hydroxyvitamin D3 on benign paroxysmal positional vertigo and risk factors. Exp Ther Med 15(3):2321–2326 Gu X, Dong F, Gu J (2018) Analysis of effect of 1α-hydroxyvitamin D3 on benign paroxysmal positional vertigo and risk factors. Exp Ther Med 15(3):2321–2326
10.
Zurück zum Zitat Sanyelbhaa H, Sanyelbhaa A (2015) Vestibular-evoked myogenic potentials and subjective visual vertical testing in patients with vitamin D deficiency/insufficiency. Eur Arch Otorhinolaryngol 272:3233–3239CrossRef Sanyelbhaa H, Sanyelbhaa A (2015) Vestibular-evoked myogenic potentials and subjective visual vertical testing in patients with vitamin D deficiency/insufficiency. Eur Arch Otorhinolaryngol 272:3233–3239CrossRef
11.
Zurück zum Zitat Yu S, Liu F, Cheng Z, Wang Q (2014) Association between osteoporosis and benign paroxysmal positional vertigo: A systematic review. BMC Neurol 14(1):110CrossRef Yu S, Liu F, Cheng Z, Wang Q (2014) Association between osteoporosis and benign paroxysmal positional vertigo: A systematic review. BMC Neurol 14(1):110CrossRef
12.
Zurück zum Zitat Mohsin FD, Alharbawi FA, Alraho ST (2019) Benign paroxysmal positional vertigo and vitamin D deficiency. Pharma Innov J 8(3):49–52 Mohsin FD, Alharbawi FA, Alraho ST (2019) Benign paroxysmal positional vertigo and vitamin D deficiency. Pharma Innov J 8(3):49–52
13.
Zurück zum Zitat Sakaida M, Takeuchi K, Ishinaga H, Adachi M, Majima Y (2003) Long-term outcome of benign paroxysmal positional vertigo. Neurology 60(9):1532–1534CrossRef Sakaida M, Takeuchi K, Ishinaga H, Adachi M, Majima Y (2003) Long-term outcome of benign paroxysmal positional vertigo. Neurology 60(9):1532–1534CrossRef
14.
Zurück zum Zitat Brandt T, Huppert D, Hecht J, Karch C, Strupp M (2006) Benign paroxysmal positioning vertigo: a long-term follow-up (6–17 years) of 125 patients. Acta Otolaryngol 126(2):160–163CrossRef Brandt T, Huppert D, Hecht J, Karch C, Strupp M (2006) Benign paroxysmal positioning vertigo: a long-term follow-up (6–17 years) of 125 patients. Acta Otolaryngol 126(2):160–163CrossRef
15.
Zurück zum Zitat Rhim GI (2016) Serum vitamin D and recurrent benign paroxysmal positional vertigo. Laryngosc Investig Otolaryngol 1(6):150–153CrossRef Rhim GI (2016) Serum vitamin D and recurrent benign paroxysmal positional vertigo. Laryngosc Investig Otolaryngol 1(6):150–153CrossRef
16.
Zurück zum Zitat Rhim LG (2019) Serum vitamin D and long term outcomes of benign paroxysmal positional vertigo. Clin Exp Otorhinolaryngol 12(3):273–278CrossRef Rhim LG (2019) Serum vitamin D and long term outcomes of benign paroxysmal positional vertigo. Clin Exp Otorhinolaryngol 12(3):273–278CrossRef
Metadaten
Titel
Relation Between Posterior Canal Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency
verfasst von
Kanika Sharma
Tarun Ojha
Rajendra Dabaria
Biban Chhabra
Bhargavi Bhaskar Trivedi
Monika Bansal
Publikationsdatum
07.01.2022
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 3/2022
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-021-03070-1

Neu im Fachgebiet HNO

ePA: Entlastung oder Mehrarbeit?

Die elektronische Patientenakte (ePA) soll das Gesundheitswesen revolutionieren. Mit über 2000 Krankenhäusern und mehr als 100.000 ärztlichen Praxen ist sie eines der größten Digitalisierungsprojekte Europas. Während die Politik die ePA als „Gamechanger“ feiert, zeigt sich in der Praxis ein anderes Bild.

Fast jeder fünfte Tinnituspatient denkt an Suizid

Von Tinnitus Betroffene schweben in erhöhter Suizidgefahr. Dies ist das Ergebnis einer Studie, wonach sowohl Suizidgedanken wie Versuche der Selbsttötung unter Tinnituspatienten häufiger sind.

Langwirksamer Antikörper bremst chronische Rhinosinusitis

Eine subkutane Injektion mit dem Antikörper Depemokimab alle sechs Monate kann die Beschwerden von Menschen mit ausgeprägter chronischer Rhinosinusitis und Nasenpolypen deutlich lindern. Dafür sprechen die Resultate von zwei Phase-3-Studien.

Kopf-Hals-Tumoren: Die Immuntherapie ist kein Selbstläufer

Ergebnisse einer weiteren Studie legen nahe: Mit einer adjuvanten Immuncheckpointhemmung ist lokal fortgeschrittenen Plattenepithelkarzinomen des Kopf-Hals-Bereichs nur schwer beizukommen. Einige Fachleute geben die Hoffnung jedoch nicht auf und diskutieren mögliche Gründe für die negativen Ergebnisse.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.